
NASDAQHealthcareBiotechnology
Latest quote
$0.797
−$0.0859 · -9.73%
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.
Previous close
$0.797
−$0.0859 · -9.73%
Regular session · ET · Market data may be delayed.
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.
Day range
Current $0.797
52-week range
Current $0.797
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
45
Fair Value
Sentiment
69
Bullish
Risk
64
High Risk
Momentum
32
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.
Day range
Current $0.797
52-week range
Current $0.797
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 213.6K USD | — | — | — | — |
| Gross profit | −213.6K USD | — | — | — | — |
| Research and development | 11.5M USD | 26.14M USD | 27.27M USD | 19.22M USD | 17.59M USD |
| Selling, general, and administrative | 11.48M USD | 25.64M USD | 11.69M USD | 9.59M USD | 6.54M USD |
| Operating expenses | 22.77M USD | 51.78M USD | 38.96M USD | 28.81M USD | 24.13M USD |
| Interest income | 435.1K USD | 1.21M USD | 387.15K USD | 152.52K USD | 2.28K USD |
| Depreciation and amortization | 213.6K USD | 291.65K USD | 192.38K USD | 148.44K USD | 149.92K USD |
| Operating income | −22.98M USD | −51.78M USD | −38.96M USD | −28.81M USD | −24.13M USD |
| Net income | −21.79M USD | −44.58M USD | −42.77M USD | −31.79M USD | −24.12M USD |
Company facts updated Nov 22, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Average target
$11.00
1280.18% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jun 24, 2025 | 1:30 | — | — |
Stock split | Jul 22, 2022 | 1:10 | — | — |
Stock split | Jul 17, 2018 | 1:10 | — | — |
Stock split | Mar 7, 2016 | 1:10 | — | — |
Stock split | Jun 16, 2014 | 1:20 | — | — |
Stock split | Apr 11, 2011 | 1:153 | — | — |
Effective Jun 24, 2025
1:30
Effective Jul 22, 2022
1:10
Effective Jul 17, 2018
1:10
Effective Mar 7, 2016
1:10
Effective Jun 16, 2014
1:20
Effective Apr 11, 2011
1:153
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.